Search Details

Word: biogen (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...last week, when word leaked out that Biogen Inc. plans to build a major recombinant DNA facility in the middle of East Cambridge, it appeared the city's historic debate over DNA had had just the opposite effect...

Author: By William E. Mckibben, | Title: The Gene-Splicers Return | 10/25/1980 | See Source »

...Biogen lawyer Kenneth Novack added that "the city has already made a decision: it could have banned DNA work outright, or left it completely laissez-faire. Instead, it chose to allow DNA research within certain regulations, regulations that we already follow...

Author: By William E. Mckibben, | Title: The Gene-Splicers Return | 10/25/1980 | See Source »

...Biogen development will differ from research conducted at Harvard and MIT in one main way--products of the research will be manufactured, at least in limited quantities, requiring what Muller termed an "upscaling" of the whole process...

Author: By William E. Mckibben, | Title: The Gene-Splicers Return | 10/25/1980 | See Source »

...Biogen S.A., which is based in Geneva, Switzerland, was the first firm to develop bacterial interferon. Founded in 1978, it is operated by a multinational board of directors and scientists. Schering-Plough last year invested $8 million in Biogen in return for exclusive worldwide manufacturing and sales rights to three of its products. Biogen has also found a second way to make interferon and is working on chemicals to cure foot-and-mouth disease, hepatitis and malaria...

Author: /time Magazine | Title: Business: Investors Dream of Genes | 10/20/1980 | See Source »

...interferon to one-twentieth of its present cost. Earlier this month G.D. Searle & Co. announced plans to build a $12 million IF plant at its research facilities in Britain. Abbott Laboratories, Warner-Lambert, Merck & Co., and a number of other companies are also gearing up for interferon production. When Biogen S.A., a Swiss firm specializing in the new recombinant DNA (gene splicing) techniques, announced in January that it had induced bacteria to produce a facsimile of human interferon, the stock of Schering-Plough, a part owner of Biogen, rose almost eight points, to 37?. Says one prominent cancer researcher...

Author: /time Magazine | Title: The Big IF in Cancer | 3/31/1980 | See Source »

Previous | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | Next